Clovis Oncology Stock Price, News & Analysis (NASDAQ:CLVS) Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.08▼$1.0952-Week Range N/AVolume1.16 million shsAverage Volume8.88 million shsMarket Capitalization$11.60 millionP/E RatioN/ADividend YieldN/APrice TargetN/A About Clovis Oncology Stock (NASDAQ:CLVS)Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.Read More CLVS Stock News HeadlinesNovember 30, 2023 | msn.comCity of Clovis hosts tree lighting ceremonyOctober 24, 2023 | msn.comFresno hospice nurse diagnosed with stage 4 cancerDecember 2, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. July 19, 2023 | thestreet.comClovis Oncology (CLVS) Stock Gains in After-Hours Trading After 'Breakthrough Therapy' DesignationJuly 6, 2023 | thestreet.comTesaro Drug Delays Recurrence of Ovarian Cancer, New Clinical Trial ShowsJuly 6, 2023 | thestreet.comWhy Clovis Oncology (CLVS) Stock Hit a One-Year Low TodayMay 21, 2023 | news.yahoo.comWing commander receives key to the city of ClovisMay 17, 2023 | news.yahoo.comNo air conditioning at Clovis East High as Fresno temperatures approach triple digitsDecember 2, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. May 11, 2023 | marketwatch.comNon-Metastatic Castration Resistant Prostate Cancer (nmCRPC) Treatment Market Size with Growth Opportunities, Top Countries Data, Future TrendsMay 7, 2023 | usnews.comClovis East High SchoolMarch 22, 2023 | marketwatch.comLuteinizing Hormone Releasing Hormone (LHRH) Agonists Market Growth, Business Development and Analysis Till 2029March 22, 2023 | news.yahoo.comTo improve representation and safety, Fresno and Clovis schools need student councils | OpinionMarch 12, 2023 | bizjournals.comSilicon Valley Bank, a 'strong supporter' of Colorado tech startups, closed by regulatorsJanuary 30, 2023 | reuters.comCLVS.OJanuary 18, 2023 | seekingalpha.comCLVSQ Clovis Oncology, Inc.January 13, 2023 | forbes.comClovis OncologyJanuary 3, 2023 | wsj.comFirm Retention Summary: Clovis Oncology Inc.December 12, 2022 | reuters.comCancer drugmaker Clovis files for bankruptcy, hit by falling salesDecember 12, 2022 | benzinga.comThinking about buying stock in Clovis Oncology, Bank of America, Rivian Automotive, Rent the Runway, or Vipshop Holdings?December 12, 2022 | bizjournals.comBoulder drugmaker Clovis Oncology files for bankruptcyDecember 12, 2022 | finance.yahoo.comClovis Plans to Sell Cancer Drug to Novartis in Bankruptcy DealDecember 12, 2022 | finance.yahoo.comClovis (CLVS) Files for Bankruptcy Amid Lack of Financial AidDecember 12, 2022 | finance.yahoo.comClovis Enters Bankruptcy With Deal to Sell Cancer-Drug Candidate to NovartisDecember 12, 2022 | investorplace.comCLVS Stock Alert: What to Know as Clovis Oncology Files for BankruptcyDecember 12, 2022 | benzinga.comCancer Focused Clovis Oncology Files For BankruptcyDecember 12, 2022 | seekingalpha.comClovis stock slumps amid Chapter 11 filing, to sell FAP-2286 to Novartis for $50M upfrontSee More Headlines Receive CLVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clovis Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/03/2021Today12/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:CLVS CUSIP18946410 CIK1466301 Webwww.clovisoncology.com Phone303-625-5000Fax303-245-0360EmployeesN/AYear Founded2009Profitability EPS (Most Recent Fiscal Year)($1.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-264,520,000.00 Net Margins-189.37% Pretax Margin-189.68% Return on EquityN/A Return on Assets-57.78% Debt Debt-to-Equity RatioN/A Current Ratio0.14 Quick Ratio0.12 Sales & Book Value Annual Sales$148.76 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($2.15) per share Price / BookN/AMiscellaneous Outstanding Shares144,955,000Free Float138,577,000Market Cap$11.60 million OptionableOptionable Beta0.24 Social Links 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Patrick J. Mahaffy MA (Age 55)Co-Founder, Chief Exec. Officer, Pres and Exec. Director Dr. Gillian C. Ivers-Read BSc (Age 64)Co-Founder, Chief Regulatory Officer and Exec. VP of Technical Operations Mr. Daniel W. Muehl CPA (Age 54)Sr. VP of Fin. and Principal Financial & Accounting Officer Dr. Lindsey Rolfe BSc (Age 50)MB ChB, MRCP, FFPM, Chief Medical Officer and Exec. VP of Clinical, Preclinical Devel. & Pharmacovigilance Mr. Corwin Dale Hooks (Age 51)Chief Commercial Officer and Sr. VP Key CompetitorsFortress BiotechNASDAQ:FBIOCatalyst BiosciencesNASDAQ:CBIORegulus TherapeuticsNASDAQ:RGLSMolecular TemplatesNASDAQ:MTEMBolt BiotherapeuticsNASDAQ:BOLTView All Competitors CLVS Stock Analysis - Frequently Asked Questions How were Clovis Oncology's earnings last quarter? Clovis Oncology (NASDAQ:CLVS) issued its quarterly earnings data on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by $0.08. The biopharmaceutical company earned $37.92 million during the quarter, compared to analyst estimates of $38.73 million. During the same period in the previous year, the company posted ($0.89) EPS. What is Patrick J. Mahaffy's approval rating as Clovis Oncology's CEO? 12 employees have rated Clovis Oncology Chief Executive Officer Patrick J. Mahaffy on Glassdoor.com. Patrick J. Mahaffy has an approval rating of 49% among the company's employees. This puts Patrick J. Mahaffy in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Clovis Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Clovis Oncology investors own include Gilead Sciences (GILD), Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Tesla (TSLA), Amarin (AMRN), Intercept Pharmaceuticals (ICPT), Netflix (NFLX) and Alibaba Group (BABA). This page (NASDAQ:CLVS) was last updated on 12/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clovis Oncology Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.